Clinical Trials Browser

Stomach Neoplasms × Specimen Handling × Gastrointestinal × Clear all

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04314401 2026-03-18

National Cancer Institute "Cancer Moonshot Biobank"

BreastDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04704661 2026-03-18

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Phase 1 Recruiting

51 enrolled

BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06995898 2026-03-18

The Vanguard Study: Testing a New Way to Screen for Cancer

Phase NA Recruiting

24,000 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06364410 2026-03-16

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Phase 1 Recruiting

48 enrolled

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT06408220 2026-03-13

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

Phase NA Recruiting

240 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05802056 2025-12-19

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Phase 1 Recruiting

15 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04213794 2025-02-20

TOASTIT

Phase EARLY_PHASE1 Terminated

2 enrolled

GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Colonic Neoplasms, Fallopian Tube Neoplasms, Liposarcoma, Ovarian Neoplasms, Pelvic Neoplasms, Rectal Neoplasms, Rhabdomyosarcoma, Sarcoma, Stomach Neoplasms, Desmoplastic Small Round Cell Tumor

NCT04535401 2024-10-10

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Phase 1 Active not recruiting

10 enrolled

Gastrointestinal

Stomach Neoplasms, Colorectal Neoplasms

NCT01445327 2022-02-01

Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers

Terminated

9 enrolled 8 charts

Gastrointestinal

Esophageal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

Clinical Trials

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

National Cancer Institute "Cancer Moonshot Biobank"

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

The Vanguard Study: Testing a New Way to Screen for Cancer

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

TOASTIT

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers